# Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

> **NCT07528586** · NA · RECRUITING · sponsor: **Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)** · enrollment: 93 (estimated)

## Conditions studied

- Cardiotoxicity
- Anthracycline-induced Cardiotoxicity

## Interventions

- **DIAGNOSTIC_TEST:** CMR based measurement of cardiotoxicity
- **OTHER:** biosampling for scientific research in study-specific biobank

## Key facts

- **NCT ID:** NCT07528586
- **Lead sponsor:** Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2029-08
- **Final completion:** 2030-03
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528586, "Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07528586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*